When was Dorian Therapeutics founded?

Dorian Therapeutics was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Dorian Therapeutics located?

Dorian Therapeutics is headquartered in San Carlos, United States.

Who is the current CEO of Dorian Therapeutics?

Maddalena Adorno of Dorian Therapeutics.

How many employees does Dorian Therapeutics have?

As of Dec 31, 2022, the latest employee count at Dorian Therapeutics is 9.

Is Dorian Therapeutics a funded company?

Dorian Therapeutics is a funded company, having raised a total of $150K across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2018.

How much is Dorian Therapeutics worth?

The last known valuation of Dorian Therapeutics was $***** as of Jan 01, 2018.

When was the latest funding round of Dorian Therapeutics?

Dorian Therapeutics' latest funding was a $***** Grant (prize money) round on May 01, 2025, with participation from 1 investor.

Where does Dorian Therapeutics rank among its competitors?

Dorian Therapeutics ranks 1116th amongst 4099 active competitors, of which 1352 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Dorian Therapeutics?

Dorian Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and argenx. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Dorian Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Dorian Therapeutics is an acquired company based in San Carlos (United States), founded in 2018 by Maddalena Adorno. It operates as a Developer of therapies for aging diseases. Dorian Therapeutics has raised $150K in funding from Y Combinator, with last known valuation of $*****. The company has 4099 active competitors, including 1352 funded and 915 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and argenx.

Company Details

Dorian Therapeutics is developing therapies for the aging in degenerative diseases and during cellular therapy. The company is using stem cell therapy, aging biology, and immunotherapy to develop its pipeline. The company has collaborated with Ubiquigent to use its ubiquitin system-based discovery platform to discover the hits targeting deubiquitylase (DUB) enzymes.

Key Metrics

Founded Year

2018

Location

San Carlos, United States

Stage

Acquired

Total Funding

$150K in 4 rounds

Latest Funding Round

Grant (prize money), May 01, 2025, $*****

Last Known Valuation

$***** as on Jan 01, 2018

Investors

Y Combinator & 2 more

Ranked

1116^th among 4099 active competitors

Employee Count

9 as on Dec 31, 2022

Similar Companies

Jazz Pharmaceuticals & 3950 more

Exit Details

Acquired by Altos Labs (May 26, 2025)

View Dorian Therapeutics' full profile

Dorian Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
DORIAN THERAPEUTICS, INC. CIN: 6936554 , United States, Active	Jun 17, 2018	-	8 (As on Dec 31, 2021)	-

Dorian Therapeutics got acquired by Altos Labs on May 26, 2025.

Click here to take a look at Dorian Therapeutics's acquisition in detail

Dorian Therapeutics has raised a total funding of $150K over 4 rounds. Its first funding round was on 2018. Its latest funding round was a Grant (prize money) round on May 01, 2025 for $*****. 1 investor participated in its latest round. Dorian Therapeutics has 3 institutional investors.

Here is the list of recent funding rounds of Dorian Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 01, 2025	8262733	Grant (prize money)	3710768	4777462	2749314	9771267
Apr 25, 2025	8457516	Grant (prize money)	2084190	7877045	9167060	HHS
Sep 23, 2021	9039553	Grant (prize money)	7999591	2412709	6095221	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Dorian Therapeutics's funding rounds and investors

The founders of Dorian Therapeutics is Maddalena Adorno.

Here are the details of Dorian Therapeutics' key team members:

Maddalena Adorno: Co-Founder & CEO of Dorian Therapeutics.
Contact Info: 1 email address

View details of Dorian Therapeutics's Founder profiles and Board Members

Dorian Therapeutics' employee count trend

Dorian Therapeutics has 9 employees as of Dec 22. The total employee count is 13.0% more than what it was in Dec 21. Here is Dorian Therapeutics's employee count trend over the years:

Employee count trend for Dorian Therapeutics

Uncover Dorian Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dorian Therapeutics include Jazz Pharmaceuticals, BeiGene and argenx. Here is the list of Top 10 competitors of Dorian Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
1116th	Dorian Therapeutics 2018, San Carlos (United States), Acquired	Developer of therapies for aging diseases	$150K	Blumberg Capital, Y Combinator & 1 others	42/100